Relyvrio

The drug's failure is a disappointment for patients and advocates, who pressed the FDA and other federal agencies to fund and approve more experimental therapies for the fatal muscle-wasting disease.

Patients with insurance coverage say the cost set by drugmaker Amylyx Pharmaceutical is fueling insurance delays or denials, and sometimes exorbitant out-of-pocket expenses.